Digital PCR quantification ofMGMTmethylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer

Liquid biopsies in patients with diffuse glioma

(2015) Myron G. Best et al.   ACTA NEUROPATHOLOGICA

Double-stranded DNA in exosomes: a novel biomarker in cancer detection

(2014) Basant Kumar Thakur et al.   CELL RESEARCH

Validation of a Real-Time PCR-Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human Plasma

(2014) N. T. Potter et al.   CLINICAL CHEMISTRY

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma

(2014) Rainer Tuominen et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

(2014) Valentina Fiano et al.   JOURNAL OF NEURO-ONCOLOGY

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

(2014) Remco J. Molenaar et al.   NEURO-ONCOLOGY

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Role of MGMT as biomarker in colorectal cancer

(2014) Alessandro Inno   World Journal of Clinical Cases

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

(2013) F. Pietrantonio et al.   ANNALS OF ONCOLOGY

Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

(2013) A. Amatu et al.   CLINICAL CANCER RESEARCH

Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells

(2013) Stefanie Kewitz et al.   LEUKEMIA RESEARCH

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter

(2013) D. Hochhauser et al.   MOLECULAR CANCER THERAPEUTICS

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome

(2013) Shadi Lalezari et al.   NEURO-ONCOLOGY

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

(2012) Consolación Melguizo et al.   Journal of Translational Medicine

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS

Response to Temozolomide in Patients With Metastatic Colorectal Cancer With Loss of MGMT Expression: A New Approach in the Era of Personalized Medicine?

(2011) Einat Shacham-Shmueli et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial

(2011) Jaime Gállego Pérez-Larraya et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

Sensitive digital quantification of DNA methylation in clinical samples

(2009) Meng Li et al.   NATURE BIOTECHNOLOGY